Loading clinical trials...
Loading clinical trials...
Phase II Study of Autologous Murine Anti-CD19 Chimeric Antigen Receptor T Cells Treating Refractory or Relapsed B Acute Lymphoblastic Leukemia Children
Conditions
Interventions
Murine autologous anti-CD19 chimeric antigen receptor T cells
Locations
1
China
Beijing Boren Hospital
Beijing, Beijing Municipality, China
Start Date
March 24, 2022
Primary Completion Date
April 3, 2024
Completion Date
April 3, 2024
Last Updated
May 18, 2025
NCT05292664
NCT06316856
NCT03128034
NCT07108868
NCT06421155
NCT06559345
Lead Sponsor
Beijing Boren Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions